BioSpace News Archive

According to The Insight Partners market research study of Continuous Positive Airway Pressure (CPAP) Devices Market to2027 - Global Analysis and Forecast by Type and End User, the global continuous positive airway pressure (CPAP) devices market is expected to reach US$ 4,481.41 million by2027 from US$ 2,462.86 million in 2019.

According to The Insight Partners market research titled ‘Surgical Retractors Market to 2027 – Global Analysis and Forecasts by Product Type, Application and End User’.

CytRx Corporation (OTCQB: CYTR) (“CytRx”), today noted that Orphazyme A/S (NASDAQ: ORPH) (“Orphazyme”) announced it has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C (“NPC”

Evergreen Therapeutics, Inc. today announced a clinical service agreement with ICON plc (“ICON”) to conduct a global, multi-center Phase II clinical trial for Evergreen’s COVID-19 drug therapy candidate EG-009A.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of company information on Neuromyelitis Optica Spectrum Disorder (NMOSD) in three oral sessions during the 7th Congress of the European Academy of Neurology (EAN), June 19 -22, 2021.

Cancer Diagnostics, Inc. (CDI), a Durham, North Carolina-based industry-leading provider of anatomic pathology products, has acquired Anatech Ltd.,

Protagonist Therapeutics, Inc. , today announced the closing of its previously announced underwritten public offering of 3,503,311 shares of its common stock.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

According to The Insight Partners market research titled ‘Vaginal Specula Market to 2027 - Global Analysis and Forecasts by Product Type, Usage, Material, Application, and End User.’

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), today announced the closing of its previously announced underwritten public offering of 15 million shares of its common stock at a price to the public of $3.00 per share.